Scientific Sessions 2025  /  Groundbreaking Trials in Cardiometabolic Therapeutics  /  Discussant
Logo

American Heart Association

  39
  0

Final ID:

Discussant

  • Gaudet, Daniel  ( ECOGENE-21 , Chicoutimi , Quebec , Canada )
    • Author Disclosures:
    Daniel Gaudet: DO have relevant financial relationships ; Consultant:Eli Lilly:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Speaker:Eli Lilly:Active (exists now) ; Speaker:Verve:Active (exists now) ; Speaker:ultragenyx:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Research Funding (PI or named investigator):Verve:Active (exists now) ; Consultant:Ultragenyx:Active (exists now) ; Research Funding (PI or named investigator):Astra zeneca:Active (exists now) ; Research Funding (PI or named investigator):Merck:Active (exists now) ; Research Funding (PI or named investigator):Ionis:Active (exists now) ; Research Funding (PI or named investigator):Arrowhead:Active (exists now) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) ; Consultant:Chiesi:Active (exists now) ; Consultant:Bio89:Active (exists now) ; Consultant:Astra Zeneca:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Verve:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Groundbreaking Trials in Cardiometabolic Therapeutics

Saturday, 11/08/2025 , 08:30AM - 09:45AM

Late-Breaking Science

More abstracts on this topic:
Olezarsen in Patients with Severe Hypertriglyceridemia: The CORE-TIMI 72a and CORE2-TIMI 72b Trials

Marston Nicholas, Zhang Shuanglu, Goodrich Erica, Murphy Sabina, Xia Shuting, Li Dan, Tsimikas Sotirios, Giugliano Robert, Sabatine Marc, Bergmark Brian, Alexander Vickie, Prohaska Thomas, Kang Yu Mi, Moura Filipe, Zimerman Andre, Waldman Elaine, Weinland Julia

DR10624, a First-In-Class, FGF21 Receptor/Glucagon Receptor/GLP-1 Receptor Triple Agonist, Rapidly and Significantly Reduced Triglycerides, Atherogenic Lipids, and Liver Fat in Patients With Severe Hypertriglyceridemia: Primary Results From a Randomized Phase 2 Trial.

Li Jianping, Zhou Zijian, Lv Lingchun, Gan Yulong, Wang Ying, Zhu Chaonan, Xu June, Huang Yanshan, Fang Yongliang, Zhang Long, Fan Yanting, Zhang Shu, Wang Liyun, Qu Yanling, Yin Guotian, Jiang Hongwei

More abstracts from these authors:
PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)

Watts Gerald, Hellawell Jennifer, Leeper Nick, Gaudet Daniel, Hegele Robert, Rosenson Robert, Goldberg Ira, Gallo Antonio, Mertens Ann, Baass Alexis, Fu Ran, Muhsin Maan

Plozasiran and Triglyceride Levels in Hypertriglyceridemia: Long-Term Efficacy and Safety Data From Subjects in an Open-Label Extension Trial

Ballantyne Christie, Muhsin Maan, Melquist Stacey, Hellawell Jennifer, Gaudet Daniel, Watts Gerald, Rosenson Robert, Vasas Szilárd, Pall Denes, Clifton Peter, Nicholls Stephen, Azizad Masoud, Fu Ran

You have to be authorized to contact abstract author. Please, Login
Not Available